Formulation Development
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients With Newly Diagnosed, Advanced Ovarian Cancer Treated With IMNN-001
IMUNON, Inc. recently announced positive topline results from the Phase 2 OVATION 2 Study with IMNN-001 in patients with advanced ovarian cancer. OVATION 2 is…
Sapio Sciences & Zifo Announce Strategic Partnership
Sapio Sciences and Zifo recently announced a strategic partnership to bring best-in-class laboratory information management solutions to customers across the biotech, clinical diagnostics, and pharmaceutical…
Dosing Completed in 115 Participant Bioavailability/Bioequivalence Clinical Trial for Proprietary Sleep Apnea Drug Candidate
Incannex Healthcare Inc. recently announce that it has completed participant dosing in the IHL-42X Bioavailability/Bioequivalence (BA/BE) clinical trial. IHL-42X comprises two drugs, dronabinol (synthetic delta-9-tetrahydrocannabinol…
CordenPharma Invests Nearly One Billion in Transformational Peptide Platform Expansion in the US & Europe
CordenPharma has announced its largest strategic investment to date with a committed spend of ~€900m over the next 3 years to grow its Peptide technology…
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
Pluri Inc. recently announced it has signed a tech transfer and manufacturing agreement with Kadimastem Ltd., a clinical stage biotechnology company developing therapeutic cells for…
Alcami Unveils New Conditions & Services at State-of-the-Art Pharma Storage Facility in Garner
Alcami Corporation has significantly expanded the cold, stability, and custom storage options at its new 65,000 ft2 state-of-the-art pharma storage facility in Garner. With a…
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug for Early Alzheimer’s Disease
Acumen Pharmaceuticals, Inc. recently announced the first subject has been dosed with a subcutaneous formulation of sabirnetug (ACU193) in a Phase 1 pharmacokinetic (PK) comparison…
Ventyx Biosciences Announces Results From Phase 2 Trial of VTX958 in Participants With Moderately to Severely Active Crohn’s Disease
Ventyx Biosciences, Inc. recently announced results from the Phase 2 trial of its allosteric TYK2 inhibitor VTX958 in participants with moderately to severely active Crohn’s…
Alpha Cognition’s Oral Therapy Receives FDA Approval to Treat Alzheimer's Disease
Alpha Cognition recently announced the US FDA has granted approval for ZUNVEYL (benzgalantamine), previously known as ALPHA-1062, for the treatment of mild-to-moderate Alzheimer's disease. Alzheimer’s…
Palisade Bio Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Lead Product Candidate
Palisade Bio, Inc. recently announced the successful completion of a microbiome study demonstrating that beta-glucuronidase is present at similar levels among dog, mouse, and human microbiota…
2024 Respiratory Drug Development eBook – CDMOs Will Become More Essential to Inhalation Device Programs
In this fifth annual Respiratory e-book, learn more about several companies and their contributions to inhalation drug delivery and device design.
WHITEPAPER - Unlock the Secrets of Spray Drying for Sticky APIs
It is widely reported that 40% of New Chemical Entities (NCEs) in the pharmaceutical industry are poorly soluble, leading to inadequate bioavailablity. Spray drying is one of the most promising particle engineering technologies….
WHITEPAPER - Versatility of Geleol™ Mono- and Diglycerides NF
Geleol exerts different functional roles, depending on the drug, formulation, and the process applied. It may serve as carrier and release modifier for oral formulations and plasticizer in tablet film coating processes. It may be combined with polymers and/or other non-digestible lipids like Compritol®….
Ipsen & Foreseen Biotechnology Announce Exclusive Global Licensing Agreement for Antibody-Drug Conjugate With First-In-Class Potential
Ipsen and Foreseen Biotechnology recently announced an exclusive global licensing agreement for FS001, an antibody-drug conjugate (ADC) with first-in-class potential. FS001 targets a novel tumor-associated…
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
OKYO Pharma Limited recently announced its plan to advance OK-101 into a Phase 2 clinical trial of neuropathic corneal pain which is expected to begin…
Rentschler Biopharma Announces New State-of-the-Art Production Line in Massachusetts is Fully Operational
Rentschler Biopharma SE recently announced the company’s new state-of-the-art production line, formerly known as the Rentschler Biopharma Manufacturing Center (RBMC), in Milford, MA, is now…
Kane Biotech Signs Worldwide License Agreement With Omni Bioceutical Innovations
Kane Biotech Inc. recently announced it has signed a worldwide license agreement with Arizona-based Omni Bioceutical Innovations Inc. for its coactiv+ line of scalp care…
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
Lisata Therapeutics, Inc. recently announced promising preclinical results for its investigational candidate, certepetide (formerly LSTA1). The data, presented in a poster by Dr. Dan G.…
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy
CARGO Therapeutics, Inc. recently announced The Lancet has published favorable data from a Phase 1, single-center clinical study (NCT04088890) by Stanford Medicine (Stanford), evaluating firi-cel,…
Oragenics Improves Intranasal Drug Formulation for Treating Concussed Patients
Oragenics, Inc. recently announced it has developed a new formulation for its novel neurosteroid. Oragenics’ lead drug candidate for concussion, ONP-002, is a new chemical…
